{
    "clinical_study": {
        "@rank": "126232", 
        "arm_group": {
            "arm_group_label": "KRX-0502", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The objective of this pilot study is to evaluate the efficacy and safety of KRX-0502,\n      administered without food, in treating iron deficiency anemia in subjects with stage 3 to 5\n      non-dialysis dependent chronic kidney disease (NDD-CKD)."
        }, 
        "brief_title": "A Pilot Study of KRX-0502 (Ferric Citrate Coordination Complex), Administered Without Food, in Treating Iron-deficiency Anemia", 
        "condition": "Anemia of Chronic Kidney Disease", 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Kidney Diseases", 
                "Deficiency Diseases", 
                "Anemia, Iron-Deficiency", 
                "Renal Insufficiency, Chronic", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Previous clinical trials have tested KRX-0502 administered with food, in dialysis-dependent\n      and NDD-CKD patients.\n\n      This clinical trial will evaluate the safety and efficacy of KRX-0502 in treating iron\n      deficiency anemia in anemic, stage III to V NDD-CKD patients in a new dosing regimen\n      (without food)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males and non-lactating females with negative serum pregnancy test (for females of\n             child-bearing potential) at Screening\n\n          -  Age > 18 years\n\n          -  Serum ferritin <300 ng/mL and TSAT <25% at Screening\n\n          -  Hemoglobin \u22659.0 g/dL and \u226411.5 g/dL at Screening\n\n          -  eGFR <60 mL/min at Screening using the 4-variable Modification of Diet in Renal\n             Disease (MDRD) equation\n\n        Exclusion Criteria:\n\n          -  Subjects receiving phosphate binder medication(s) at, or within 4 weeks prior to,\n             screening\n\n          -  Symptomatic gastrointestinal bleeding, inflammatory bowel disease, inflammatory bowel\n             syndrome and/or Crohn's Disease within 24 weeks prior to \\ Screening\n\n          -  Evidence of acute kidney injury or requirement for dialysis within 8 weeks prior to\n             Screening\n\n          -  Kidney transplant anticipated or start of dialysis expected within 16 weeks of\n             Screening\n\n          -  History of hemochromatosis\n\n          -  IV iron administered within 4 weeks prior to Screening\n\n          -  Erythropoiesis-Stimulating Agent (ESA) administered within 4 weeks prior to Screening\n\n          -  Blood transfusion within 4 weeks prior to Screening\n\n          -  Receipt of any investigational drug within 4 weeks prior to Screening\n\n          -  Cause of anemia other than iron deficiency or chronic kidney disease\n\n          -  History of malignancy in the last five years\n\n          -  Active drug or alcohol dependence or abuse (excluding tobacco use) within the 12\n             months prior to Screening\n\n          -  Any known allergies to iron products\n\n          -  Previous intolerance to oral ferric citrate\n\n          -  Psychiatric disorder that interferes with the subject's ability to comply with the\n             study protocol\n\n          -  Planned surgery or hospitalization during the trial\n\n          -  Any other medical condition that, in the opinion of the PI, renders the subject\n             unable to or unlikely to complete the trial or that would interfere with optimal\n             participation in the trial or produce significant risk to the subject"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02128074", 
            "org_study_id": "KRX-0502-207"
        }, 
        "intervention": {
            "arm_group_label": "KRX-0502", 
            "intervention_name": "KRX-0502 (ferric citrate)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Citric Acid"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 29, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Naharyia", 
                        "country": "Israel"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nazareth", 
                        "country": "Israel"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tel Aviv", 
                        "country": "Israel"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2 Pilot Study of KRX-0502 (Ferric Citrate Coordination Complex) in Treating Iron-deficiency Anemia in Patients With Stage 3-5 Non-dialysis Dependent Chronic Kidney Disease (NDD-CKD)", 
        "overall_contact": {
            "email": "shay.shemesh@keryx.com", 
            "last_name": "Shay Shemesh, MS", 
            "phone": "2125315966"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in hemoglobin over an 8-week treatment period", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02128074"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Keryx Biopharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Keryx Biopharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}